EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

被引:2086
|
作者
Singh, A. [1 ]
Settleman, J. [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA
关键词
EMT; cancer; cancer stem cells; drug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; MIR-200; FAMILY; E-CADHERIN; LUNG-CANCER; REPRESSORS ZEB1; SMAD PROTEINS;
D O I
10.1038/onc.2010.215
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumors are cellularly and molecularly heterogeneous, with subsets of undifferentiated cancer cells exhibiting stem cell-like features (CSCs). Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. The EMT process can be regulated by a diverse array of cytokines and growth factors, such as transforming growth factor (TGF)-beta, whose activities are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in the acquisition of invasive and metastatic properties. Recent reports indicate that the emergence of CSCs occurs in part as a result of EMT, for example, through cues from tumor stromal components. Recent evidence now indicates that EMT of tumor cells not only causes increased metastasis, but also contributes to drug resistance. In this review, we will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs. We will also highlight recent studies implicating the function of TGF-beta-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal. Finally we will discuss how EMT and CSCs may contribute to drug resistance, as well as therapeutic strategies to overcome this clinically. Oncogene (2010) 29, 4741-4751; doi: 10.1038/onc.2010.215; published online 7 June 2010
引用
收藏
页码:4741 / 4751
页数:11
相关论文
共 50 条
  • [1] EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
    A Singh
    J Settleman
    Oncogene, 2010, 29 : 4741 - 4751
  • [2] Pancreatic cancer stem cells and EMT in drug resistance and metastasis
    Sarkar, F. H.
    Li, Y.
    Wang, Z.
    Kong, D.
    MINERVA CHIRURGICA, 2009, 64 (05) : 489 - 500
  • [3] Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance
    Elgendy, Sara M.
    Alyammahi, Shatha K.
    Alhamad, Dima W.
    Abdin, Shifaa M.
    Omar, Hany A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 155
  • [4] Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance
    Wang, Zhiwei
    Li, Yiwei
    Ahmad, Aamir
    Azmi, Asfar S.
    Kong, Dejuan
    Banerjee, Sanjeev
    Sarkar, Fazlul H.
    DRUG RESISTANCE UPDATES, 2010, 13 (4-5) : 109 - 118
  • [5] Drug resistance and Cancer stem cells
    Li, Yuan
    Wang, Zhenning
    Ajani, Jaffer A.
    Song, Shumei
    CELL COMMUNICATION AND SIGNALING, 2021, 19 (01)
  • [6] Drug resistance and Cancer stem cells
    Yuan Li
    Zhenning Wang
    Jaffer A. Ajani
    Shumei Song
    Cell Communication and Signaling, 19
  • [7] Cancer stem cells and the EMT
    Weinberg, Robert A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells
    Lee, Yong Sang
    Kim, Seok-Mo
    Kim, Bup-Woo
    Chang, Ho Jin
    Kim, Soo Young
    Park, Cheong Soo
    Park, Ki Cheong
    Chang, Hang-Seok
    NEOPLASIA, 2018, 20 (02): : 197 - 206
  • [9] Influence of cancer stem cells on drug resistance in prostate cancer
    Castellon, E. A.
    Castillo, V.
    Valenzuela, R.
    Contreras, H. R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S75 - S75
  • [10] Cancer Stem Cells: The Emerging Challenge of Drug Targeting
    Besancon, Roger
    Valsesia-Wittmann, Sandrine
    Puisieux, Alain
    de Fromentel, Claude Caron
    Maguer-Satta, Veronique
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (04) : 394 - 416